University of Miami

WEDNESDAY, Jan. 15, 2025 -- Tobacco-associated trachea, bronchus, and lung (TBL) cancer mortality is declining, while ambient particulate matter (PM)-associated TBL cancer mortality is increasing, according to a study published in the January issue of eClinicalMedicine . Chinmay T. Jani, M.B.B.S., from the Sylvester Comprehensive Cancer Center at the University of Miami, and colleagues extracted overall and risk factor-associated TBL cancer age-standardized mortality rates (ASMRs) in the 10 most populated countries for 1990 to 2019 from the Global Burden of Disease database to examine trends. The researchers found that globally, there was an 8 percent decrease in TBL cancer mortality, with a decrease for men and an increase for women. Decreases were seen in both tobacco- and air pollution-associated TBL cancer ASMRs globally. Tobacco-associated ASMRs increased in China and Indonesia, and increases in air pollution-associated ASMRs were seen in China, India, Pakistan, and Nigeria. On stratification, PM-associated mortality increased by 25 percent globally, while there was a 62 percent decrease in household-associated TBL cancer ASMRs. In 2019, China had the highest PM-associated TBL cancer ASMR (8.8/100,000), which was twofold higher than the global average. There was a decline seen in asbestos-associated TBL cancer ASMRs, from 8.91 to 6.0/100,000; however, for the entire study period, the rate in the United States remained twofold higher than the global average. "The fluctuating trends in tobacco-associated and the concerning rise in air pollution-associated TBL cancer mortality highlight the complex interplay of societal and environmental factors," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc. (“VisiRose”), Provectus’s Founded Entity that is developing novel ocular therapeutics. VisiRose is a newly launched, privately held, clinical-stage biotechnology company focused on initially commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB-PDAT”) for the treatment of infectious keratitis and other eye infections using Provectus’s bioactive synthetic small molecule and active pharmaceutical ingredient (“API”) Rose Bengal Sodium (“RBS”). RB-PDAT, a groundbreaking, non-invasive investigational treatment for eye infections, is based on innovative ocular research from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (“BPEI”) of the University of Miami’s Miller School of Medicine. RB-PDAT combines a formulation of Provectus’s pharmaceutical-grade RBS API and OBC’s light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms. VisiRose’s seed financing round supports several key ongoing initiatives: Preparing for and completing a pre-investigational new drug (“IND”) submission meeting with the U.S. Food and Drug Administration (“FDA”) for RB-PDAT for infectious keratitis,Preparing and submitting an IND application for investigational eye drug PV-305, and working towards the IND’s acceptance by the FDA,Manufacturing an initial clinical supply of PV-305 for VisiRose to initiate clinical trials and undertake expanded access post-IND acceptance, andApplying for Small Business Innovative Research grant funding to support VisiRose’s clinical development of RB-PDAT for infectious keratitis and to undertake more novel research with BPEI. Dominic Rodrigues, Vice Chairman of the Board of Directors and President of Provectus, who also serves as Acting Chief Executive Officer of VisiRose, said, “We are pleased that VisiRose completed this first financing round to support the advancement of its ophthalmology drug pipeline. The funding enables VisiRose to advance its lead drug candidate PV-305 through critical initial regulatory steps, ultimately moving VisiRose and Provectus closer to providing patients with innovative therapies for corneal diseases and other serious ocular conditions.” VisiRose’s website is accessible here: https://visirose.com/. About VisiRose VisiRose is a newly launched, privately held, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine’s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center’s innovative ocular research using Provectus’s bioactive synthetic small molecule Rose Bengal Sodium (“RBS”). For more information, please visit https://visirose.com. About Bascom Palmer Eye Institute Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2024-2025, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 23rd time and 21st consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 35 years ago. About Provectus Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is RBS. Provectus’s small molecule drug platform includes: Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com. Forward Looking Statements The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including those described in Item 1A of Provectus’s: Annual Report on Form 10-K for the period ended December 31, 2023, andQuarterly Report on Form 10-Q for the period ended September 30, 2024. Contacts: Provectus Biopharmaceuticals, Inc.Heather Raines, CPAChief Financial Officerhraines@pvct.com (866) 594-5999 VisiRose, Inc.Dominic RodriguesActing Chief Executive Officerrodrigues@visirose.com (866) 216-7333 Investor Relations & MediaAlliance Advisors Investor RelationsIra M. Gostinigostin@allianceadvisors.com(775) 391-0213

KNOXVILLE, TN / ACCESSWIRE / January 14, 2025 / VisiRose Inc. (\"VisiRose\" or the \"Company\"), a privately-held, clinical-stage biotechnology company developing novel ocular therapeutics, today announced a $3 million seed financing round for VisiRose. The funds from this round will be directed toward advancing the Company\'s lead investigational program, particularly facilitating critical regulatory milestones of the clinical development of its therapies for corneal diseases and other severe ocular conditions.The proceeds from this financing round will support several key initiatives, including:Completing a pre-investigational new drug (IND) submission meeting with the U.S. Food and Drug Administration (FDA) for VisiRose\'s Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive, investigational treatment for infectious keratitis and other serious eye infections.Submitting an IND application for investigational drug PV-305, targeting corneal blindness (RB) through photodynamic therapy (PDAT), and working toward its acceptance by the FDA.Manufacturing an initial clinical supply of PV-305, enabling the Company to initiate clinical trials, undertake expanded access, and move closer to regulatory approval.VisiRose is leveraging the novel ocular RB PDAT research from the University of Miami\'s Bascom Palmer Eye Institute and Ophthalmic Biophysics Center, in collaboration with Provectus Biopharmaceuticals (OTCQB: PVCT). At the heart of the Company\'s therapeutic platform is Provectus\'s bioactive synthetic small molecule, Rose Bengal Sodium (RBS), to treat a range of sight-threatening ocular conditions with high unmet medical needs.\"We are pleased to complete this financing round to support the continued progress of our ophthalmology drug pipeline,\" said Dominic Rodrigues, Acting Chief Executive Officer of VisiRose. \"The funding will enable us to advance our lead drug product candidate PV-305 through critical regulatory steps, ultimately moving us closer to providing patients with innovative therapies for corneal diseases and other serious ocular conditions.\"Juan Carlos Navia, M.D. at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, delivering the VisiRose RB PDAT treatment. Courtesy of Bascom Palmer Eye Institute About VisiRoseVisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine\'s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center\'s innovative ocular research using Provectus\'s bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.Contact:VisiRose, Inc.Dominic RodriguesActing Chief Executive Officer[email protected]For Media Inquiries:Ira M. Gostin[email protected]775-391-0213SOURCE: VisiRose, Inc.Related Documents: